Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial is a research paper published in Intensive Care Medicine (2021). On theSindex it has a DataRank of 1.5. It has been cited 55 times, with 40 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph â no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full â never from an abstract alone.
Base Score Contribution
0.604
From this paper's citation signal
Citation Network Contribution
0.922
From 31 citing papers with measurable signal
Ranked by each citer's contribution to N(p) â log1p(Cq) divided by its reference count â out of 40 citers.
National Institute on Alcohol Abuse and Alcoholism
Grant: R42AA024003
Innovate UK
Grant: 102165
MultiStem for the Treatment of Acute Respiratory Distress Syndrome
National Institutes of Health
Grant: 4R42AA024003-02
Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
NIAID NIH HHS
Grant: U19 AI135964
NCATS NIH HHS
Grant: UL1 TR001422
NHLBI NIH HHS
Grant: P01 HL154998
FWCI
5.92
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapyâcontrolled, phase 2 multicenter study (ONE-BRIDGE)
Additional file 1 of Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapyâcontrolled, phase 2 multicenter study (ONE-BRIDGE)
Additional file 2 of Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapyâcontrolled, phase 2 multicenter study (ONE-BRIDGE)
Additional file 2 of Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapyâcontrolled, phase 2 multicenter study (ONE-BRIDGE)
Additional file 10 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 8 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 9 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 9 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 10 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 4 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 4 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 7 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 3 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 8 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 1 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 7 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 5 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 2 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 6 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice
Additional file 1 of Dose-specific efficacy of adipose-derived mesenchymal stem cells in septic mice